7 results about "Alcoholic hepatitis" patented technology

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

To provide a bifunctional degrading agent for interleukin-1 receptor-related kinases and its therapeutic use. [Solution] This disclosure provides a bifunctional compound as an IRAK4 degradation agent via the ubiquitin-proteasome pathway, and a method for treating diseases modulated by IRAK4. The compounds of this disclosure or their pharmaceutical compositions are useful as therapeutic agents for treating inflammatory disorders such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, necrotizing enterocolitis, gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases including chronic kidney disease and diabetic kidney disease.

The present disclosure relates to methods of predicting liver disease mortality using lipoprotein LP-Z. Described herein are methods for determining patient mortality of alcoholic hepatitis in a biological sample by NMR spectroscopy, and more particularly, methods for determining a Z index score based on the lipoprotein fraction LP-Z in plasma and serum.

Provided herein are therapeutic agents and compositions for treating infections associated with alcohol-associated hepatitis. Also provided herein are methods of expanding the host range of an Enterococcus faecalis, E. faecalis bacteriophage for the treatment of an alcohol-associated hepatitis associated infection.

This disclosure relates, in general, to a process for preparing compounds that are inhibitors of the kinase IRAK4, and to synthetic intermediates prepared thereby. IRAK4 inhibitors may be useful in the treatment of inflammatory and fibrous disorders, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases, including chronic kidney disease and diabetic kidney disease.

25HC3S choline and crystalline 25HC3S choline are described herein.Further disclosed herein is the pharmaceutical preparation of 25HC3S choline, for example, using crystalline 25HC3S choline, and the method of using it to treat or prevent diseases, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic condition, autoimmune condition, inflammatory condition, neurological condition, Epstein-Barr virus-related proliferation and the condition related to fat accumulation and inflammation.Also provided is the method of preparing 25HC3S, including crystalline 25HC3S choline.

Several salts of 25HC3S are provided, including crystalline salts of 25HC3S. Pharmaceutical formulations of the disclosed salts and methods for using them to treat or prevent diseases, such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus-associated proliferation, and conditions associated with fat accumulation and inflammation, are also provided. Methods for preparing the disclosed salts are also provided.